The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.

The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

Therapeutic advances have significantly improved leukaemia survival rates, but this progress does not apply to all forms of the disease. Chronic myelomonocytic leukaemia (CMML) remains ...

Her medical history was notable for chronic myelomonocytic leukemia, diagnosed 6 years previously ... of disease was ultimately complicated by acute disseminated encephalomyelitis and death.

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Leukemic involvement of the gastrointestinal tract must be considered in any patient with acute or chronic leukemia who presents with unusual gastrointestinal symptoms, or in any patient with ...

Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E.